1. Home
  2. BDTX vs OZKAP Comparison

BDTX vs OZKAP Comparison

Compare BDTX & OZKAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Logo Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

OZKAP

Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

N/A

Current Price

$15.43

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
OZKAP
Founded
2014
N/A
Country
United States
United States
Employees
N/A
3351
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
171.9M
N/A
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BDTX
OZKAP
Price
$1.97
$15.43
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$9.67
N/A
AVG Volume (30 Days)
487.0K
25.9K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
130.71
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$15.50
52 Week High
$4.94
$17.85

Technical Indicators

Market Signals
Indicator
BDTX
OZKAP
Relative Strength Index (RSI) 41.85 19.01
Support Level $1.61 N/A
Resistance Level $2.28 $16.57
Average True Range (ATR) 0.10 0.20
MACD -0.03 -0.08
Stochastic Oscillator 3.75 7.84

Price Performance

Historical Comparison
BDTX
OZKAP

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About OZKAP Bank OZK 4.625% Series A Non-Cumulative Perpetual Preferred Stock

Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides banking services, including checking, savings, money market, time deposits, and individual retirement accounts, as well as loan services, such as real estate, consumer, commercial, and industrial loans. Apart from providing traditional banking products and services, it also provides trust and wealth management, financial planning, online banking, and other related services.

Share on Social Networks: